Previous Close | 398.00 |
Open | 397.75 |
Bid | 401.70 x 30000 |
Ask | 405.75 x 30000 |
Day's Range | 397.75 - 403.90 |
52 Week Range | 274.30 - 403.90 |
Volume | |
Avg. Volume | 62 |
Market Cap | 131.534B |
Beta (5Y Monthly) | 1.42 |
PE Ratio (TTM) | 16.82 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 10.24 (2.57%) |
Ex-Dividend Date | May 30, 2024 |
1y Target Est | N/A |
Transcendia Holdings, Inc. ("Transcendia" or the "Company"), a leader in manufacturing and converting custom engineered films, today announced it has entered into an agreement for a recapitalization transaction that will strengthen the Company's financial position and create a sustainable, long-term capital structure for the next phase of growth. The transaction will provide Transcendia with $114 million in new capital, eliminate more than $200 million of the Company's debt and further strengthe
Ms. Salka brings more than 30 years of healthcare leadership and staffing expertise, including strong C-suite, financial and ESG expertise to advance the company’s Patients-first focus and growth initiativesDURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Susan R. Salka, retired Chief Executive Officer and President
DirectBooks, a global leader in primary markets communications, announced today that Santander, Ramirez & Co. and Mischler Financial Group have joined the platform. The recent additions increase the number of underwriters participating on DirectBooks to 34 worldwide.